Ronald Bentsur
Amministratore Delegato presso NUVECTIS PHARMA, INC.
Patrimonio netto: 21 M $ in data 30/04/2024
Posizioni attive di Ronald Bentsur
Società | Posizione | Inizio | Fine |
---|---|---|---|
NUVECTIS PHARMA, INC. | Amministratore Delegato | 27/07/2020 | - |
Presidente | 27/07/2020 | - | |
Fondatore | 27/07/2020 | - | |
Presidente | 27/07/2020 | - | |
BEYOND AIR, INC. | Direttore/Membro del Consiglio | 01/08/2015 | - |
Independent Dir/Board Member | 01/08/2015 | - | |
Beyond Air Ltd.
Beyond Air Ltd. BiotechnologyHealth Technology Beyond Air, Ltd. is a clinical-stage medical device and biopharmaceutical company engaging in the development of nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. The company was founded by Yossef Av-Gay, Amir Avniel, and David Greenberg in May 2011 and is headquartered in Rehovot, Israel. | Direttore/Membro del Consiglio | 01/01/2017 | - |
Presidente | 01/08/2015 | 01/01/2017 | |
Ait Ltd.
Ait Ltd. BiotechnologyHealth Technology Ait Ltd. engages in research and development in biotechnology. The private company is located in Israel. The Israeli company was founded by Yossef Av-Gay, Amir Avniel, Avishai Abrahami. Amir Avniel has been the CEO of the company since 2011. | Presidente | 01/08/2015 | - |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Consulente / Consigliere | - | - |
Storia della carriera di Ronald Bentsur
Precedenti posizioni note di Ronald Bentsur
Società | Posizione | Inizio | Fine |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/01/2009 | 01/06/2020 |
UROGEN PHARMA LTD. | Direttore/Membro del Consiglio | 01/10/2015 | 03/01/2019 |
Amministratore Delegato | 01/08/2015 | 03/01/2019 | |
KERYX BIOPHARMACEUTICALS | Direttore/Membro del Consiglio | 16/06/2009 | 30/04/2015 |
Amministratore Delegato | 20/05/2009 | 30/04/2015 | |
XTL BIOPHARMACEUTICALS LTD. | Amministratore Delegato | 01/01/2006 | 01/04/2009 |
░░░░░ ░░░░░░░░░░░░░░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Formazione di Ronald Bentsur
The Hebrew University of Jerusalem | Undergraduate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Statistiche
Distribuzione geografica
Israele | 8 |
Stati Uniti | 7 |
Posizioni
Director/Board Member | 6 |
Chief Executive Officer | 4 |
Chairman | 3 |
Settori
Health Technology | 10 |
Consumer Services | 3 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 5 |
---|---|
XTL BIOPHARMACEUTICALS LTD. | Health Technology |
UROGEN PHARMA LTD. | Health Technology |
NEXTGEN BIOMED LTD | Health Technology |
NUVECTIS PHARMA, INC. | Health Technology |
BEYOND AIR, INC. | Health Technology |
Aziende private | 6 |
---|---|
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Beyond Air Ltd.
Beyond Air Ltd. BiotechnologyHealth Technology Beyond Air, Ltd. is a clinical-stage medical device and biopharmaceutical company engaging in the development of nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. The company was founded by Yossef Av-Gay, Amir Avniel, and David Greenberg in May 2011 and is headquartered in Rehovot, Israel. | Health Technology |
Leumi Partners Underwriters Ltd. | |
Ait Ltd.
Ait Ltd. BiotechnologyHealth Technology Ait Ltd. engages in research and development in biotechnology. The private company is located in Israel. The Israeli company was founded by Yossef Av-Gay, Amir Avniel, Avishai Abrahami. Amir Avniel has been the CEO of the company since 2011. | Health Technology |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
- Borsa valori
- Insiders
- Ronald Bentsur
- Esperienza